What did we learn from the OPTIMAAL trial? What can we expect from VALIANT? - Abstract
- Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …

Role of ACE inhibitors in the management of asymptomatic or symptomatic left ventricular
(LV) dysfunction after acute myocardial infarction (AMI) is well established. More recently …

BACKGROUND: The VALIANT trial compared the efficacy and safety of captopril, valsartan,
and their combination in patients with left ventricular systolic dysfunction, heart failure, or …

BACKGROUND: The causes of death occurring in clinical trials of myocardial infarction (MI)
are scarcely reported in the literature. The present analysis is aimed to describe the …

Experimental studies and molecular biological techniques have demonstrated the
importance of angiotensin II in ventricular and vascular remodelling and in atherogenesis …

There is an increasing body of clinical trial evidence to support the use of angiotensin-
converting enzyme (ACE) inhibitors in the management of patients following myocardial …

The role of angiotensin receptor blockers (ARBs) in patients with left ventricular dysfunction
has changed after the VALIANT and CHARM trials. CHARM proved that candesartan is a …

Nearly 100 years ago, Tigerstedt and Bergman (1898) observed that renal extracts may
increase blood pressure. In 1934, Goldblatt and associates described their animal model for …

There is a tremendous spectrum of disease severity within the diagnosis of myocardial
infarction. The risk of major cardiovascular outcomes is highly related to age and …

OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist
Losartan) is the first major study to compare an angiotensin II Type 1 antagonist losartan …